Form 4: ANAB CEO Faga Reports Routine Stock Transactions

AnaptysBio CEO Daniel Faga reported the acquisition of shares from RSU vesting and a subsequent 'sell to cover' transaction for tax obligations.

Summary

• Daniel Faga, President, CEO, and Director of AnaptysBio, Inc. (ANAB), reported transactions involving the company's common stock.
• On January 3, 2026, Faga acquired 34,677 shares of common stock through the settlement of Restricted Stock Units (RSUs).
• This acquisition increased his direct beneficial ownership to 473,448 shares, which includes 2,305 shares acquired under the Company's Employee Stock Purchase Plan (ESPP).
• Concurrently, 34,677 derivative Restricted Stock Units (RSUs) were converted into common stock.
• On January 5, 2026, Faga disposed of 15,309 shares of common stock at a price of $43.26 per share.
• This sale was a 'sell to cover' transaction, specifically executed to satisfy tax withholding obligations related to the vesting and settlement of RSUs, and was not a discretionary sale.
• Following these transactions, Faga's direct beneficial ownership of common stock stands at 458,139 shares.
• The RSUs vest as to 25% of the total annually, commencing on January 3, 2025, contingent on continued service.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to equity compensation. The acquisition of shares from RSU vesting and ESPP participation is a positive sign of executive alignment, while the 'sell to cover' transaction for tax purposes is a standard, non-discretionary event. Overall, it's a neutral to slightly positive report as it reflects the execution of pre-existing compensation plans.

Positives

• Acquisition of 34,677 shares of common stock through RSU settlement, indicating a conversion of equity incentives into direct ownership.
• Beneficial ownership includes 2,305 shares acquired under the Company's ESPP, suggesting participation in employee stock programs.
• RSUs continue to vest annually at 25% starting January 3, 2025, demonstrating ongoing long-term incentive alignment.

Negatives

• Disposition of 15,309 shares of common stock, reducing direct beneficial ownership.
• The sale price of $43.26 per share represents a cash outflow for the company's stock.

Future Outlook

RSUs will continue to vest annually at 25% commencing on January 3, 2025, subject to Daniel Faga's continued provision of service to AnaptysBio, Inc.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This Form 4 filing reports a routine insider transaction related to equity compensation, which is common practice across all industries, particularly in biotechnology where executive compensation often includes significant equity components. It does not provide information relevant to broader industry trends or competitors.

Comparison to Industry Standards

• The 'sell to cover' transaction for tax withholding is a standard practice for executives receiving equity compensation (like RSUs) across publicly traded companies globally. This mechanism allows executives to meet tax liabilities without needing to use personal funds, ensuring compliance while retaining a significant portion of their vested equity. No specific comparable companies or projects are mentioned in this filing.

Stakeholder Impact

• Shareholders: Minor impact. The transactions are routine and pre-planned, reflecting the execution of executive compensation. The 'sell to cover' is not a discretionary sale indicating a change in sentiment.
• Employees: No direct impact mentioned, but the ESPP participation highlights an employee benefit program.
• Management: Daniel Faga's beneficial ownership remains substantial, aligning his interests with shareholders.

Next Steps

• Continued annual vesting of remaining Restricted Stock Units (RSUs) at 25% commencing on January 3, 2025.

Key Dates

Recommendation

This Form 4 details routine, pre-planned insider transactions related to executive compensation (RSU vesting and a 'sell to cover' for taxes) and ESPP participation. Such transactions are common and do not typically signal a change in the company's fundamental outlook or the insider's discretionary view on the stock. Therefore, it provides no new information that would warrant a change in investment recommendation based solely on this filing.

Keywords

ANAB, AnaptysBio, Form 4, insider transaction, stock transaction, RSU, ESPP, Daniel Faga, equity compensation